63,629 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Chiron Investment Management LLC

Chiron Investment Management LLC purchased a new stake in Boston Scientific Co. (NYSE:BSX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 63,629 shares of the medical equipment provider’s stock, valued at approximately $5,683,000. Boston Scientific makes up approximately 1.9% of Chiron Investment Management LLC’s investment portfolio, making the stock its 19th largest holding.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Sunbelt Securities Inc. increased its holdings in Boston Scientific by 16.6% in the third quarter. Sunbelt Securities Inc. now owns 1,414 shares of the medical equipment provider’s stock valued at $118,000 after buying an additional 201 shares during the last quarter. M&T Bank Corp raised its position in shares of Boston Scientific by 0.3% during the 3rd quarter. M&T Bank Corp now owns 106,127 shares of the medical equipment provider’s stock worth $8,894,000 after acquiring an additional 370 shares in the last quarter. Passumpsic Savings Bank acquired a new position in Boston Scientific in the third quarter valued at approximately $3,015,000. World Investment Advisors LLC increased its stake in Boston Scientific by 50.9% in the third quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider’s stock valued at $979,000 after purchasing an additional 3,939 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Boston Scientific during the third quarter worth approximately $1,175,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, CFO Daniel J. Brennan sold 15,087 shares of Boston Scientific stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the transaction, the chief financial officer now owns 241,451 shares of the company’s stock, valued at $25,369,256.57. The trade was a 5.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 133,183 shares of company stock valued at $13,948,476. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Performance

Shares of BSX opened at $93.66 on Monday. The company has a market capitalization of $138.53 billion, a PE ratio of 74.93, a P/E/G ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a 52-week low of $66.80 and a 52-week high of $107.17. The company has a 50-day simple moving average of $100.54 and a 200-day simple moving average of $94.10. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the subject of several research analyst reports. Stifel Nicolaus upped their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Wells Fargo & Company lifted their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Argus set a $130.00 target price on Boston Scientific in a research report on Tuesday, February 18th. JPMorgan Chase & Co. lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Barclays increased their price objective on Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $109.04.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.